Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 13 | 2018 | 232 | 2.440 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2013 | 77 | 1.460 |
Why?
|
| Estradiol | 7 | 2014 | 262 | 1.340 |
Why?
|
| Motor Activity | 6 | 2014 | 418 | 0.860 |
Why?
|
| Nucleus Accumbens | 2 | 2021 | 82 | 0.820 |
Why?
|
| Social Isolation | 1 | 2021 | 29 | 0.790 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2021 | 26 | 0.780 |
Why?
|
| Dopamine | 2 | 2021 | 245 | 0.750 |
Why?
|
| Estrogens | 4 | 2008 | 202 | 0.670 |
Why?
|
| Rats | 15 | 2021 | 3483 | 0.560 |
Why?
|
| Testosterone | 2 | 2010 | 193 | 0.540 |
Why?
|
| Estrogen Antagonists | 2 | 2014 | 28 | 0.500 |
Why?
|
| GTP-Binding Proteins | 2 | 2004 | 60 | 0.460 |
Why?
|
| Cues | 1 | 2013 | 55 | 0.460 |
Why?
|
| Conditioning, Operant | 1 | 2013 | 73 | 0.450 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2014 | 1618 | 0.440 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 156 | 0.430 |
Why?
|
| Ovariectomy | 6 | 2013 | 105 | 0.420 |
Why?
|
| Behavior, Animal | 5 | 2013 | 314 | 0.330 |
Why?
|
| Brain | 6 | 2018 | 1346 | 0.320 |
Why?
|
| Animals | 17 | 2021 | 15081 | 0.320 |
Why?
|
| Benzeneacetamides | 1 | 2008 | 6 | 0.320 |
Why?
|
| Pyrrolidines | 1 | 2008 | 29 | 0.310 |
Why?
|
| Analgesics | 1 | 2008 | 54 | 0.300 |
Why?
|
| Cathepsin B | 2 | 2018 | 26 | 0.290 |
Why?
|
| Receptors, GABA-B | 1 | 2004 | 11 | 0.250 |
Why?
|
| Cerebrovascular Circulation | 1 | 2005 | 70 | 0.250 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 143 | 0.250 |
Why?
|
| Oxygen | 2 | 2005 | 207 | 0.250 |
Why?
|
| Ventral Tegmental Area | 1 | 2004 | 36 | 0.240 |
Why?
|
| Sex Characteristics | 2 | 2005 | 230 | 0.240 |
Why?
|
| Macrophages | 2 | 2018 | 439 | 0.220 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2003 | 73 | 0.220 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2002 | 17 | 0.210 |
Why?
|
| Narcotics | 1 | 2002 | 32 | 0.210 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2002 | 53 | 0.210 |
Why?
|
| Neurons | 2 | 2014 | 1175 | 0.200 |
Why?
|
| Neuroprotective Agents | 2 | 2014 | 245 | 0.200 |
Why?
|
| Potassium | 1 | 2021 | 112 | 0.190 |
Why?
|
| Spinal Cord Injuries | 2 | 2014 | 56 | 0.180 |
Why?
|
| Drug Implants | 3 | 2014 | 21 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1039 | 0.180 |
Why?
|
| Female | 13 | 2018 | 20969 | 0.170 |
Why?
|
| Ethylenediamines | 1 | 2018 | 7 | 0.160 |
Why?
|
| Receptors, sigma | 1 | 2018 | 15 | 0.160 |
Why?
|
| HIV Infections | 3 | 2018 | 2303 | 0.160 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 5 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2008 | 141 | 0.130 |
Why?
|
| Isoflurophate | 1 | 2014 | 10 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 221 | 0.120 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 2004 | 7 | 0.120 |
Why?
|
| Autoradiography | 2 | 2004 | 36 | 0.120 |
Why?
|
| Anxiety | 1 | 2021 | 754 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2014 | 43 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2014 | 85 | 0.120 |
Why?
|
| Diterpenes | 1 | 2014 | 92 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2014 | 65 | 0.120 |
Why?
|
| Proteomics | 1 | 2015 | 325 | 0.110 |
Why?
|
| Male | 6 | 2021 | 20025 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2014 | 121 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2010 | 35 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 481 | 0.090 |
Why?
|
| Sexual Behavior, Animal | 1 | 2011 | 53 | 0.090 |
Why?
|
| Antioxidants | 1 | 2014 | 416 | 0.090 |
Why?
|
| Brain Mapping | 1 | 2011 | 112 | 0.090 |
Why?
|
| Time Factors | 3 | 2014 | 1742 | 0.090 |
Why?
|
| HIV-1 | 1 | 2014 | 706 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 14 | 0.080 |
Why?
|
| Receptor, EphA4 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 550 | 0.070 |
Why?
|
| Tegmentum Mesencephali | 1 | 2005 | 1 | 0.060 |
Why?
|
| Hypercapnia | 1 | 2005 | 8 | 0.060 |
Why?
|
| Baclofen | 1 | 2004 | 8 | 0.060 |
Why?
|
| Consciousness | 1 | 2004 | 5 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2005 | 140 | 0.060 |
Why?
|
| GABA Agonists | 1 | 2004 | 21 | 0.060 |
Why?
|
| Entorhinal Cortex | 1 | 2004 | 13 | 0.060 |
Why?
|
| Limbic System | 1 | 2004 | 25 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2004 | 79 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 513 | 0.060 |
Why?
|
| Sulfur Radioisotopes | 1 | 2003 | 7 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 251 | 0.060 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2003 | 12 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2003 | 111 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2004 | 444 | 0.060 |
Why?
|
| Quinpirole | 1 | 2003 | 16 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2003 | 30 | 0.060 |
Why?
|
| Muscarinic Agonists | 1 | 2002 | 10 | 0.050 |
Why?
|
| Pilocarpine | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 290 | 0.050 |
Why?
|
| Reward | 1 | 2003 | 79 | 0.050 |
Why?
|
| Kainic Acid | 1 | 2002 | 48 | 0.050 |
Why?
|
| Stereotyped Behavior | 1 | 2002 | 22 | 0.050 |
Why?
|
| Naloxone | 1 | 2002 | 52 | 0.050 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2002 | 48 | 0.050 |
Why?
|
| Corticosterone | 1 | 2002 | 77 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 143 | 0.050 |
Why?
|
| Hippocampus | 1 | 2005 | 561 | 0.050 |
Why?
|
| Apoptosis | 2 | 2018 | 1398 | 0.040 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 40 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 628 | 0.040 |
Why?
|
| Morpholines | 1 | 2018 | 69 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2018 | 207 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 1371 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 893 | 0.030 |
Why?
|
| Oxygen Isotopes | 1 | 2015 | 5 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 2005 | 64 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1354 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 15 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 19 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 2014 | 55 | 0.030 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2014 | 34 | 0.030 |
Why?
|
| Seizures | 1 | 2014 | 68 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2014 | 94 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2014 | 88 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 111 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 267 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 461 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2011 | 35 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2011 | 89 | 0.020 |
Why?
|
| Middle Aged | 2 | 2015 | 10129 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 1518 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1492 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 11712 | 0.020 |
Why?
|
| Humans | 3 | 2018 | 37093 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4268 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 938 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 5913 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 39 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2006 | 33 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 70 | 0.020 |
Why?
|
| Hyperalgesia | 1 | 2006 | 18 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 189 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2006 | 171 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 136 | 0.020 |
Why?
|
| Biogenic Monoamines | 1 | 2005 | 31 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 103 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 77 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 623 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2005 | 107 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2006 | 484 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1207 | 0.010 |
Why?
|